Breaks Categories: Stock Spotlights

WednesdayMar 05, 2025 3:30 pm

BioMedNewsBreaks — Adageis: Shaping the Future of Healthcare with AI-Powered Solutions

Adageis offers AI-driven solutions that help providers transition to and optimize value-based care models. “Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services rendered. This approach incentivizes proactive care, chronic disease management and overall cost efficiency,” a recent article explains. “Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is helping providers streamline their transition to value-based models. Through its ProActive Care Platform, Adageis enables healthcare organizations to optimize patient care while maximizing…

Continue Reading

WednesdayMar 05, 2025 2:42 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent article. “Calidi’s pipeline includes the proprietary SuperNova (‘SNV’) platform, which utilizes allogeneic adipose-derived mesenchymal stem cells (‘AD-MSCs’) as carriers for antitumor virotherapy. This approach has shown promise in preclinical studies and safety studies, with potential applications…

Continue Reading

ThursdayFeb 27, 2025 3:26 pm

BioMedNewsBreaks — Adageis Tackling Healthcare’s Value-Based Shift with AI-Driven Insights, Seamless Integration

Adageis, a forward-thinking healthcare technology company, is bringing AI-driven solutions that help providers harness data to improve care efficiency and financial performance amid an industry shift from fee-for-service models to value-based care. “A major hurdle in value-based care is identifying high-risk patients before they require costly interventions. Adageis addresses this with its Patented Risk Engine (‘PRE’), which analyzes clinical and demographic data to flag individuals most likely to develop chronic conditions or experience hospital readmissions. By surfacing these insights in real time, providers can intervene earlier, reducing avoidable emergency visits and improving long-term health outcomes,” reads a recent article. “Another…

Continue Reading

ThursdayFeb 20, 2025 1:29 pm

BioMedNewsBreaks — Adageis: Championing the Future of Healthcare with Powerful AI Tools

Adageis is positioned for opportunity as artificial intelligence reshapes healthcare. The technology company offers “flexible AI-centric software solutions for healthcare systems and providers in an easy-to-use application driving higher revenue… Its powerful and patented AI-centric ProActive Care Platform integrates seamlessly into existing workflows, making it an ideal partner for organizations navigating the shift toward value-based care,” reads a recent article. “Adageis’ proactive efficiency tools enable real-time monitoring, ensuring that patients receive timely interventions between visits. This approach reduces emergency department utilization and improves patient satisfaction… By prioritizing targeted solutions, Adageis not only transforms care delivery but also sets a benchmark for…

Continue Reading

FridayFeb 14, 2025 3:48 pm

BioMedNewsBreaks — Adageis Bringing AI Solutions to Identify High-Risk Patients, Address Care Gaps

Adageis is reshaping the healthcare landscape, offering solutions designed to streamline workflows and align incentives with quality care outcomes. “Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (‘ACOs’), Clinically Integrated Networks (‘CINs’), and Independent Physician Associations (‘IPAs’) with the tools to deliver high-quality care while meeting the financial goals of value-based models,” reads a recent article. “At the heart of the platform lies the Patented Risk Engine (‘PRE’), an AI-driven tool that analyzes patient data to identify high-risk individuals and care gaps.…

Continue Reading

TuesdayFeb 11, 2025 1:30 pm

BioMedNewsBreaks — Adageis Seizing Opportunity in AI-Driven Healthcare Innovation

Adageis is positioned to capitalize as artificial intelligence (“AI”) plays a crucial role in meeting quality metrics, reducing costs and improving patient outcomes in the transition toward value-based healthcare. While the sector faces challenges — such as integrating AI tools into existing systems, ensuring data security and navigating regulatory frameworks — innovators like Adageis, a forward-thinking healthcare technology company, are stepping in to bridge the gap, offering scalable solutions that align with modern needs. “Adageis is at the forefront of AI-driven healthcare innovation. Its ProActive Care Platform provides providers, clinics and health systems with tools to enhance care delivery while addressing…

Continue Reading

WednesdayFeb 05, 2025 3:00 pm

BioMedNewsBreaks — Astiva Health’s Focus on Multilingual Support, Tailored Solutions Driving Its Success

Astiva Health now serves more than 30,000 members, an increase that reflects the growing demand for the company’s unique, culturally aligned health care model. “The increase in membership comes as Astiva earned a prestigious 4-star CMS rating for 2025, placing it among the top-rated Medicare Advantage providers in California,” reads a recent article. “This membership surge reflects the growing demand for Astiva’s culturally aligned health care model. The emphasis on multilingual support and culturally responsive services has made the company a leader in inclusive health care. In addition, partnerships with local businesses and activity centers have enabled Astiva to foster meaningful…

Continue Reading

WednesdayJan 22, 2025 2:30 pm

BioMedNewsBreaks — Adageis at Forefront of Shift to Value-Based Care

Adageis is structured to support providers during a transformation of the U.S. healthcare system, shifting from fee-for-service models to value-based care. The company’s unique offering of tools and solutions simplify the necessary moves, including AI-driven analytics and patient-focused care solutions. “This transition prioritizes quality outcomes over service volume but requires a dramatic overhaul of infrastructure, culture and operations. Adageis, a forward-thinking healthcare technology company, is at the forefront of this shift, with its focus on revolutionizing patient care through innovative value-based solutions,” reads a recent article. “Adageis has all the tools needed to support providers during this transformation. Its ProActive Care…

Continue Reading

MondayJan 13, 2025 2:59 pm

BioMedNewsBreaks — Adageis’s Platform Empowering Organizations to Adjust to New Risk-Scoring Dynamics

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model. “The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage… The more precise structure enhances diagnostic specificity, allowing for better patient categorization. This change supports value-based care by tying payments more closely to actual patient needs,” reads a recent article. “The CMS-HCC transition aligns closely with Adageis’s mission of…

Continue Reading

WednesdayJan 08, 2025 2:29 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Continue Reading